Maxygen Gets $90 Million Cash Infusion From Bayer For Hemophilia Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal will build on Bayer’s hemophilia experience with Kogenate, and provide cash for Maxygen to explore autoimmune programs.